Skip to main content

Advertisement

SpringerLink
Log in

Recurring Outbreaks of Circulating Vaccine-derived Polioviruses: Implications for Global Poliovirus Immunization Strategy

  • Perspective
  • Published:
Indian Pediatrics Aims and scope Submit manuscript

Abstract

The incidence of polio has decreased by more than 99.9% and currently, only two countries are endemic for wild poliovirus. However, increasing outbreaks of circulating vaccine-derived poliovirus globally in the last few years, with the latest ones in high-income, exclusive inactivated polio virus vaccine (IPV)-using countries have brought out a new dimension to the end game of polio eradication. The inability of the current IPV to induce efficient mucosal immunity in the intestine is likely to be one of the key reasons behind the silent transmission of the polio virus in these countries. New challenges demand concerted global efforts with renewed vigor to cross the last mile. We need to aggressively cover up areas of under-vaccination and continue large-scale genomic surveillance. Further, the availability of a novel oral polio vaccine (nOPV2), and the likely availability of Sabin IPV and a more refined IPV with mucosal adjuvant in the near future is likely to go a long way in achieving this remarkable feat.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Global Polio Eradication Initiative. Endemic countries. Accessed on Nov 22, 2022. Available from: https://polioeradication.org/where-we-work/polio-endemic-countries/

  2. Lai YA, Chen X, Kunasekaran M, Rahman B, MacIntyre CR. Global epidemiology of vaccine-derived poliovirus 2016–2021: A descriptive analysis and retrospective case-control study. EClinicalMedicine. 2022;50:101508.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Circulating vaccine-derived poliovirus. Accessed on Dec 22, 2022. Available from: https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/

  4. World Health Organization. Two out of three wild poliovirus strains eradicated. Accessed on Dec 22, 2022. Available from: https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated

  5. Thompson KM, Kalkowska DA, Badizadegan K. Health economic analysis of vaccine options for the polio eradication endgame: 2022–2036. Expert Rev Vaccines. 2022; 21:1667–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. World Health Organization. Detection of circulating vaccine derived polio virus 2 (cVDPV2) in environmental samples–the United Kingdom of Great Britain and Northern Ireland and the United States of America. Accessed on Nov 22, 2022. Available from: Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON408

  7. Zuckerman NS, Bar-Or I, Sofer D, et al. Emergence of genetically linked vaccine-originated poliovirus type 2 in the absence of oral polio vaccine, Jerusalem, April to July 2022. Euro Surveill. 2022;27:2200694.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Connor RI, Brickley EB, Wieland-Alter WF, et al. Mucosal immunity to poliovirus. Mucosal Immunol. 2022;15:1–9.

    Article  CAS  PubMed  Google Scholar 

  9. Kubagawa H, Bertoli LF, Barton JC, Koopman WJ, Mestecky J, Cooper MD. Analysis of paraprotein transport into the saliva by using anti-idiotype antibodies. J Immunol. 1987;138:435–9.

    Article  CAS  PubMed  Google Scholar 

  10. Brickley EB, Strauch CB, Wieland-Alter WF, et al. Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine. J Infect Dis. 2018;217:371–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sun H, Sun C, Xiao W, Sun R. Tissue-resident lymphocytes: from adaptive to innate immunity. Cell Mol Immunol. 2019; 16: 20515.

    Article  Google Scholar 

  12. Wright PF, Prevost-Reilly AC, Natarajan H, et al. Longitudinal systemic and mucosal immune responses to SARS-CoV-2 infection. J Infect Dis. 2022;226:1204–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Liew F, Talwar S, Cross A, et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalization with COVID-19 and is not induced by subsequent vaccination. EBioMedicine. 2022: 104402.

  14. Bandyopadhyay AS, Gast C, Brickley EB, et al. A randomized phase 4 study of immunogenicity and safety after monovalent oral type 2 Sabin poliovirus vaccine challenge in children vaccinated with inactivated poliovirus vaccine in Lithuania. J Infect Dis. 2021;223:119–27.

    Article  CAS  PubMed  Google Scholar 

  15. Ghendon YZ, Sanakoyeva II. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin’s strains) in persons after naturally and experimentally acquired immunity. Acta Virol. 1961;5:256–73.

    Google Scholar 

  16. Grassly NC, Jafari H, Bahl S, Sethi R, Deshpande JM, Wolff C, et al. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis. 2012;205:1554–61.

    Article  CAS  PubMed  Google Scholar 

  17. Macklin G, Peak C, Eisenhawer M, Kurji F, Mach O, Konz J, et al. Enabling accelerated vaccine roll-out for public health emer-gencies of international concern (PHEICs): novel oral polio vaccine type 2 (nopv2) experience. Vaccine. 2022:S0264–410X (22)00195-5.

  18. Clinical summary for novel oral polio vaccine type 2 (nOPV2). Accessed on Dec 28, 2022. Available from: https://polioeradication.org/wp-content/uploads/2020/05/Clinical-development-summary-nOPV2-20200521.pdf

  19. Kimbal S. CDC is discussing using oral polio vaccine for first time in 20 years to stop New York outbreak. CNBC, October 21, 2022. Accessed on Dec 2, 2022. Available from: https://www.cnbc.com/2022/10/21/cdc-is-discussing-using-oral-polio-vaccine-for-first-time-in-20-years-to-stop-new-york-outbreak.html

  20. Global Polio Eradication Initiative. Affordable IPV. Accessed on Dec 3, 2022. Available from: https://polioeradication.org/tools-and-library/current-research-areas/affordable-ipv/

  21. Macklin GR, Grassly NC, Sutter RW, et al. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis. Lancet Infect Dis. 2019;19:1121–8.

    Article  CAS  PubMed  Google Scholar 

  22. Norton EB, Bauer DL, Weldon WC, Oberste MS, Lawson LB, Clements JD. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine. 2015; 33:1909–15.

    Article  CAS  PubMed  Google Scholar 

  23. Sáez-Llorens X, Bandyopadhyay AS, Gast C, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021; 397:27–38.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Chumakov K, Brechot C, Gallo RC, Plotkin S. Choosing the right path toward polio eradication. Accessed on Feb 13, 2023. Available from: https://www.nejm.org/doi/pdf/10.1056/NEJMp2215257

Download references

Funding

None

Author information

Authors and Affiliations

  1. Department of Pediatrics, Mangla Hospital and Research Center, Bijnor, Uttar Pradesh, India

    Vipin M. Vashishtha

  2. Kumar Child Clinic, KM Chowk, Sector 12, Dwarka, New Delhi, India

    Puneet Kumar

Authors
  1. Vipin M. Vashishtha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Puneet Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vipin M. Vashishtha.

Additional information

Competing interests

None stated.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vashishtha, V.M., Kumar, P. Recurring Outbreaks of Circulating Vaccine-derived Polioviruses: Implications for Global Poliovirus Immunization Strategy. Indian Pediatr 60, 437–441 (2023). https://doi.org/10.1007/s13312-023-2904-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13312-023-2904-3

Keywords

Search

Navigation